论文部分内容阅读
组织因于途径抑制物（TFPI）为血浆中一种新发现的抗凝蛋白，其含量变化与某些恶性肿瘤、血栓性疾病及弥散性血管内凝血（DIC）等相关，国内尚无类似研究。我们测定了急性非淋巴细胞白血病（ANLL）及Ⅱ型糖尿病（NIDDM）患者血浆中TFPI抗原含量与活性，现报道如下。对象和方法1
Tissue Pathway Inhibitor (TFPI) is a newly discovered anticoagulant protein in plasma, and its content is related to some malignant tumors, thrombotic diseases, and disseminated intravascular coagulation (DIC). There is no similar study in China. . We measured plasma TFPI antigen levels and activity in patients with acute non-lymphocytic leukemia (ANLL) and type 2 diabetes (NIDDM) and are reported below. Object and Method 1